Avicanna Inc
Company Profile
Business description
Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.
Contact
480 University Avenue
Suite 1502
TorontoBCM5G 1V2
CANT: +1 647 243-5283
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
87
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,853.70 | 60.20 | -0.76% |
| CAC 40 | 7,104.80 | 21.22 | -0.30% |
| DAX 40 | 20,374.10 | 188.63 | -0.92% |
| Dow JONES (US) | 40,212.71 | 619.05 | 1.56% |
| FTSE 100 | 7,964.18 | 50.93 | 0.64% |
| HKSE | 20,914.69 | 232.91 | 1.13% |
| NASDAQ | 16,724.46 | 337.14 | 2.06% |
| Nikkei 225 | 33,585.58 | 1,023.42 | -2.96% |
| NZX 50 Index | 12,019.13 | 182.30 | -1.49% |
| S&P 500 | 5,363.36 | 95.31 | 1.81% |
| S&P/ASX 200 | 7,646.50 | 63.10 | -0.82% |
| SSE Composite Index | 3,238.23 | 14.59 | 0.45% |